217 related articles for article (PubMed ID: 34175896)
21. Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy.
Downes MR; Xu B; van der Kwast TH
Eur J Cancer; 2021 May; 148():432-439. PubMed ID: 33077335
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Roobol MJ; Helleman J; van Leenders GJLH
Histopathology; 2020 Apr; 76(5):755-762. PubMed ID: 31944367
[TBL] [Abstract][Full Text] [Related]
23. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
[TBL] [Abstract][Full Text] [Related]
24. Cribriform morphology is associated with higher risk of biochemical recurrence after radical prostatectomy in patients with Grade Group 5 prostate cancer.
Oufattole J; Dey T; D'Amico AV; van Leenders GJLH; Acosta AM
Histopathology; 2023 Jun; 82(7):1089-1097. PubMed ID: 36939057
[TBL] [Abstract][Full Text] [Related]
25. Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Akamatsu S; Terada N; Miyazawa Y; Narita S; Haba R; Sugimoto M
Jpn J Clin Oncol; 2023 Oct; 53(10):984-990. PubMed ID: 37496400
[TBL] [Abstract][Full Text] [Related]
26. Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.
Rijstenberg LL; Hansum T; Kweldam CF; Kümmerlin IP; Remmers S; Roobol MJ; van Leenders GJLH
Histopathology; 2022 Jun; 80(7):1041-1049. PubMed ID: 35384019
[TBL] [Abstract][Full Text] [Related]
27. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy.
Miyake H; Muramaki M; Furukawa J; Tanaka H; Inoue TA; Fujisawa M
Urol Oncol; 2013 Nov; 31(8):1511-6. PubMed ID: 22658882
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
[TBL] [Abstract][Full Text] [Related]
30. Prostatic Ductal Adenocarcinoma Controlled for Tumor Grade, Stage, and Margin Status Does Not Independently Influence the Likelihood of Biochemical Recurrence in Localized Prostate Cancer After Radical Prostatectomy.
Kryvenko ON; Iakymenko OA; De Lima Guido LP; Bhattu AS; Merhe A; Mouzannar A; Briski LM; Oymagil I; Lugo I; Nemov I; Ritch CR; Kava BR; Punnen S; Jorda M; Parekh DJ; Gonzalgo ML
Arch Pathol Lab Med; 2022 Aug; 146(8):1012-1017. PubMed ID: 34739539
[TBL] [Abstract][Full Text] [Related]
31. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; van der Kwast TH; Roobol MJ; van Leenders GJ
Mod Pathol; 2016 Jun; 29(6):630-6. PubMed ID: 26939875
[TBL] [Abstract][Full Text] [Related]
32. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.
Okubo Y; Sato S; Hasegawa C; Koizumi M; Suzuki T; Yamamoto Y; Yoshioka E; Ono K; Washimi K; Yokose T; Kishida T; Miyagi Y
Hum Pathol; 2023 May; 135():99-107. PubMed ID: 36738975
[TBL] [Abstract][Full Text] [Related]
33. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer.
Czaja RC; Tarima S; Wu R; Palagnmonthip W; Iczkowski KA
Ann Diagn Pathol; 2021 Jun; 52():151725. PubMed ID: 33610958
[TBL] [Abstract][Full Text] [Related]
34. Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2.
Leo P; Chandramouli S; Farré X; Elliott R; Janowczyk A; Bera K; Fu P; Janaki N; El-Fahmawi A; Shahait M; Kim J; Lee D; Yamoah K; Rebbeck TR; Khani F; Robinson BD; Shih NNC; Feldman M; Gupta S; McKenney J; Lal P; Madabhushi A
Eur Urol Focus; 2021 Jul; 7(4):722-732. PubMed ID: 33941504
[TBL] [Abstract][Full Text] [Related]
35. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
[TBL] [Abstract][Full Text] [Related]
36. Prognostic influence of the third Gleason grade in prostatectomy specimens.
Cedeño Díaz OM; Fernández Aceñero MJ; Alvarez Fernández E
Urol Oncol; 2012; 30(4):386-90. PubMed ID: 21292510
[TBL] [Abstract][Full Text] [Related]
37. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
38. Comedonecrosis within conventional prostatic adenocarcinoma vs. intraductal carcinoma of the prostate: their clinical significance is not comparable.
Wang Y; Teramoto Y; Miyamoto H
Hum Pathol; 2023 Aug; 138():112-120. PubMed ID: 37364826
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic Study of Gleason Pattern 5 Prostatic Adenocarcinoma With "Single-cell" Growth Reveals 2 Distinct Types, One With "Plasmacytoid" Features.
Nguyen JK; Chen YY; Magi-Galluzzi C; McKenney JK
Am J Surg Pathol; 2020 Dec; 44(12):1635-1642. PubMed ID: 32991340
[TBL] [Abstract][Full Text] [Related]
40. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
